Insider transactions

OrbiMed Capital GP III LLC

CIK 1432241 · last filed 2018-05-02

OrbiMed Capital GP III LLC is a corporate insider who has filed 23 SEC Form 4 insider transactions across 9 companies since 2011. The most recent filing shows the insider sold $6.3M of PIRS on May 2, 2018. Across all open-market trades the lifetime net is −$119.8M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $89.6M across reported positions. The firm reports its address in New York, NY. 70 SEC filings were submitted jointly with ORBIMED ADVISORS LLC.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure
$89.64M
Companies
9
Total Filings
23
Lifetime Open-Market Net
-$119.81M

Charts

Trading activity, where the exposure sits, and each trade against the stock price.

AMRN price and trades

Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.

Shares held

Shares owned after each reported transaction on this company (direct holdings as reported).

Open-market buying and selling

by month

Dollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.

Exposure by company

latest
OfficerDirector10% owner* stale (no filing in 3 yrs)

Most recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.

Filer Profile

Reported Address
601 LEXINGTON AVENUE
54TH FLOOR
NEW YORK, NY 10022
Phone
(212) 749-6400
State of Incorporation
DE
Related Filers
ORBIMED ADVISORS LLC — 70 joint filings, latest 2018-08-21
Samuel D Isaly — 61 joint filings, latest 2018-01-04
PALVELLA THERAPEUTICS, INC. — 6 joint filings, latest 2018-05-02
Pacira BioSciences, Inc. — 6 joint filings, latest 2012-03-13
OrbiMed Advisors Ltd — 4 joint filings, latest 2016-12-01
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
PALVELLA THERAPEUTICS, INC. (PIRS) Delisted Director 486 $13.60 $6.6K -$4.97M 2 2018-05-02
GKOS Director 445 $236.99 $105.5K -$36.66M 3 2018-03-06
Roka BioScience, Inc. (ROKA) Delisted 10%+ Owner 809,386 — — $4.58M 2 2017-08-25
ViewRay, Inc. (VRAY) Delisted Director 9,041,883 $0.03 $226.0K $3.36M 1 2016-08-24
Cartesian Therapeutics, Inc. (SELB) Delisted Director 17,382 $0.88 $15.3K $7.70M 1 2016-06-29
Sientra, Inc. (SIEN) Delisted 10%+ Owner 176,790 $0.17 $30.8K -$6.04M 4 2015-10-13
AMBIT BIOSCIENCES CORP (AMBI) Delisted 10%+ Owner 378,122 $0.54 $204.0K $5.42M 1 2013-05-22
AMRN Director 29,715 $11.73 $348.6K -$95.83M 7 2012-09-05
PCRX 10%+ Owner 2,446,000 $36.46 $89.18M $2.64M 2 2012-03-13

Recent Filings

23 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2018-05-02 PALVELLA THERAPEUTICS, INC. (PIRS) Delisted Sell (S) −1,000,000 -$6.35M EDGAR
2018-03-06 GKOS Sell (S) −836,500 -$26.79M EDGAR
2017-08-25 Roka BioScience, Inc. (ROKA) Delisted Sell (S) −14,300 -$21.4K EDGAR
2016-08-24 ViewRay, Inc. (VRAY) Delisted Buy (P) +1,138,074 $3.36M EDGAR
2016-08-12 GKOS Sell (S) −292,938 -$9.87M EDGAR
2016-06-29 Cartesian Therapeutics, Inc. (SELB) Delisted Mixed +1,727,995 $7.70M EDGAR
2015-10-13 Sientra, Inc. (SIEN) Delisted Sell (S) −287,891 -$1.72M EDGAR
2015-10-06 Sientra, Inc. (SIEN) Delisted Sell (S) −193,000 -$1.68M EDGAR
2015-10-01 Sientra, Inc. (SIEN) Delisted Sell (S) −101,898 -$1.04M EDGAR
2015-09-28 Sientra, Inc. (SIEN) Delisted Sell (S) −150,908 -$1.60M EDGAR
Showing 1–10 of 23
Page 1 of 3
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.